Taltz gets approval for age 6 + psoriasis patients

[Fred]

Taltz is now approved by the FDA (U.S. Food and Drug Administration) for use in children over 6 years.

Quote:

---

Eli Lilly announced today the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for Taltz® (ixekizumab) injection, 80 mg/mL for the treatment of pediatric patients (ages 6 to under 18) with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Source: lilly.com

Taltz (ixekizumab)